2020201920182017201620152014 January 31, 2020 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 30, 2020 Summary ToggleSpero Therapeutics Announces Proposed Rights Offering January 13, 2020 Summary ToggleSpero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense December 04, 2019 Summary ToggleSpero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease November 29, 2019 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 26, 2019 Summary ToggleSpero Therapeutics to Host Key Opinion Leader Symposium in December November 04, 2019 Summary ToggleSpero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline Review October 31, 2019 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 03, 2019 Summary ToggleSpero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial September 30, 2019 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination First page First Previous page Previous … Page 3 Current page 4 Page 5 Page 6 … Next page Next Last page Last
